Occurrence of Myocarditis after the Vaccine for COVID-19
Rapid Review of Incidence, Associated Risk Factors, and Clinical Course of Myocarditis and Pericarditis following COVID-19 vaccination
Project Status:Complete
Knowledge User(s)
Public Health Agency of Canada, National Advisory Committee on Immunization
Patient/Public Partner(s)
Linda Wilhelm, Natasha Trehan
Funding Source(s)
- Canadian Institutes of Health Research (CIHR) through COVID-END
- Canadian Institutes of Health Research (CIHR) through the Strategy for Patient-Oriented Research (SPOR) Evidence Alliance
Project Objectives
To determine what the incidence of myocarditis and pericarditis is after COVID-19 vaccination; whether the incidence varies by patient characteristics (e.g., age, sex) or vaccine factors (e.g., type of vaccine, dose); and the characteristics and short-term clinical course in patients with myocarditis and pericarditis after COVID-19 vaccination.
Research Approach
Rapid Review
Project Lead(s)
Lisa Hartling
Dr. Lisa Hartling is a professor in the Department of Pediatrics at the University of Alberta. She is a Canada Research Chair (Tier 1) in Knowledge Synthesis and Translation, and holds several directorships or co-directorships including the following: Alberta Research Centre for Health Evidence (ARCHE); University of Alberta Evidence Review Synthesis Centre; Translating Emergency Knowledge for Kids; and Cochrane Child Health. She is also a co-convenor of the Cochrane Comparing Multiple Interventions Methods Group.
Lisa Hartling
Alberta Research Centre for Health Evidence, University of Alberta
Dr. Lisa Hartling is a professor in the Department of...